Warning out on cancer drug | Inquirer News

Warning out on cancer drug

By: - Reporter / @santostinaINQ
/ 10:37 PM May 24, 2014

Photo from fda.gov.ph

MANILA, Philippines—The Food and Drug Administration is warning the public against buying a cancer treatment medicine that may cause health complications due to cracks in the vials.

In an advisory, FDA acting Director General Kenneth Hartigan Go advised patients with cancer of the blood not to buy Bortezomib (Velcade) 3.5 mg Lyophilized Powder for Injection (IV/SC) with batch numbers 102424, 102430, 102501, 102502 and 102648.

Article continues after this advertisement

These batches had been reported in the United States and Germany to have cracked vials, Go said.

FEATURED STORIES

Bortezomib is used to treat multiple myeloma, a cancer of the blood.

Go urged doctors and their patients to inspect all their vials of the product for any damage before use.

Article continues after this advertisement

Those who had bought the medicine and found cracks may contact the FDA through [email protected] or Janssen Pharmaceutica at tel. (632)8248968 or [email protected].

Article continues after this advertisement

“Any suspected adverse reactions experienced from the product should be reported immediately to the FDA by visiting www.fda.gov.ph.,” Go said.

RELATED STORIES

Fake dietary tablets seized in NBI raids

FDA warns of unregistered eye drops

Warning out on 2 recalled drugs

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Cancer, drug, FDA

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.